Mechanism — how Tesamorelin and CJC-1295 differ
Tesamorelin is a stabilised 44-amino-acid analogue of native human GHRH with a trans-3-hexenoyl modification at the N-terminus that protects against DPP-4 degradation while preserving the full 44-residue sequence.
CJC-1295 is a truncated 30-residue GHRH analogue with four amino-acid substitutions that increase resistance to enzymatic degradation. The 'with DAC' variant adds a drug-affinity-complex (maleimidopropionic acid) modification that promotes covalent albumin binding and substantially extends the half-life; the 'no DAC' variant is the unmodified short analogue.
Receptor profile
Both compounds act as agonists at the GHRH receptor, driving pulsatile growth-hormone release through the native pituitary axis. The downstream IGF-1 response in research models follows the GH pulse.
Tesamorelin's full 44-residue sequence preserves the receptor-binding geometry of native GHRH more closely than the truncated CJC-1295 sequence; CJC-1295 with DAC trades some receptor-binding fidelity for a substantially longer pharmacokinetic profile.
Pharmacokinetics and half-life
Tesamorelin has an extended pharmacokinetic profile relative to native GHRH thanks to the trans-3-hexenoyl modification — daily research cadence is typical. CJC-1295 no DAC sits in a similar daily-cadence window.
CJC-1295 with DAC has a substantially longer half-life — multi-day, suitable for weekly research cadence — driven by covalent albumin binding through the DAC modification. The trade-off is a less pulsatile GH-release profile and a sustained rather than pulsatile IGF-1 signal in research models.
Research applications
Tesamorelin is widely used in metabolic, lipodystrophy and body-composition research models, often in the same protocol arms as the published clinical literature. It remains the GHRH-axis reference compound for full-sequence work.
CJC-1295 no DAC is used when a short-acting, pulsatile GHRH-axis research compound is needed. CJC-1295 with DAC is used when a sustained, multi-day GHRH-axis profile is needed — typically paired with ipamorelin in growth-hormone secretagogue research panels.
Analytical specification on every Regena batch
Both Tesamorelin and CJC-1295 ship from Regena only after independent third-party verification — Janoshik Analytical is the default verifier, with orthogonal independent laboratories used when batch chemistry calls for confirmation by a second method. Minimum release specification is ≥99.0% HPLC main-peak purity with matching mass-spectrometry molecular weight and water content within the published specification for the compound.
Batch COAs for both compounds are published on the Regena lab reports page so a research-peptide buyer can audit the analytical detail before purchase. The /trust/how-to-read-a-coa reference walks through every field on a modern Regena COA.
Handling, reconstitution and stability
Both compounds ship lyophilised under nitrogen. Hold the unopened vial at 2–8 °C; freeze at −20 °C for long-term storage. Reconstitution with bacteriostatic water (0.9% benzyl alcohol) supports a 28-day in-use stability window under refrigeration. Light exposure should be minimised for both compounds during reconstitution and storage.
Aliquot before any freeze. The single most common cause of measurable potency loss in research peptides is repeat freeze-thaw cycling — both Tesamorelin and CJC-1295 benefit from single-thaw aliquot workflows. Vortex gently, never shake aggressively, and keep reconstituted vials away from direct light. The /research/compound-storage-guide reference covers the per-compound stability windows in detail.
When researchers choose Tesamorelin vs CJC-1295
Researchers choose tesamorelin when the protocol requires the full 44-residue GHRH-axis activation with a daily research cadence and when leveraging the published clinical literature is part of the project design. Researchers choose CJC-1295 no DAC when a short-acting pulsatile profile is needed, and CJC-1295 with DAC when a sustained multi-day profile (often paired with ipamorelin) is the experimental requirement.
For multi-compound comparator studies, the Regena consultations team will reserve matched-batch inventory of both Tesamorelin and CJC-1295 against a project timeline so the experimental panel is sourced under a single analytical specification window.
Regulatory and research-use framing
Both Tesamorelin and CJC-1295 are supplied strictly for in-vitro and preclinical research use. They are not medicines, are not approved for human consumption in Spain, the United Kingdom, the European Union or the United States, and are not dispensed against a prescription. The research-use declaration ships with every package alongside the independent third-party COA.
Comparison pages on the Regena site exist for laboratory-research reference. Nothing on this page constitutes a recommendation for human use of either compound.
Frequently asked questions
What is the main difference between Tesamorelin and CJC-1295?+
Tesamorelin is a stabilised 44-amino-acid analogue of native human GHRH with a trans-3-hexenoyl modification at the N-terminus that protects against DPP-4 degradation while preserving the full 44-residue sequence..
Which has the longer half-life, Tesamorelin or CJC-1295?+
Tesamorelin has an extended pharmacokinetic profile relative to native GHRH thanks to the trans-3-hexenoyl modification — daily research cadence is typical. CJC-1295 no DAC sits in a similar daily-cadence window.
Are Tesamorelin and CJC-1295 the same compound class?+
Both sit in the GHRH analogues category but with distinct receptor profiles and pharmacokinetics — see the receptor-profile section above for the side-by-side detail.
What HPLC purity does Regena release each compound against?+
≥99.0% HPLC main-peak purity for both Tesamorelin and CJC-1295, with matching mass-spectrometry molecular weight and water content within the published specification for each compound.
Who independently verifies the batches?+
Janoshik Analytical is the default independent verifier for both compounds; orthogonal independent laboratories are used when batch chemistry calls for second-method confirmation.
Can I order matched batches for a comparator study?+
Yes — the Regena consultations team will reserve matched-batch inventory of both compounds against a project timeline so the experimental panel is sourced under a single analytical specification window.
Are these peptides approved for human use?+
No. Both are supplied strictly for in-vitro and preclinical research use. They are not medicines, are not approved for human consumption, and are not dispensed against a prescription.
Where can I see the current batch COAs for both compounds?+
On the /coa lab reports page, indexed by compound and batch number. New batches appear within 24 hours of independent release.
Recommended next — keep comparing
Hand-picked links our research customers most often open after this page.